In the specialized world of biochemistry and contract manufacturing, the term polypeptide 483 often surfaces in two distinct, yet equally important, domains. For those of us who follow the technical side of peptide synthesis and regulatory documentation, it is essential to distinguish between the scientific nomenclature used in laboratory research and the administrative terminology found in regulatory oversight.
Navigating Regulatory Documentation: The FDA 483 Form
When professionals encounter the term "483" in the context of manufacturing, it by EJ AMBROSE · 1949 · Cited by 109 — A STUDY of polypeptides prepared by Leuchs's method1,2 is being carried out in this Laboratory. We have recently prepared the polypeptide I (below) by the almost exclusively refers to the FDA 483 form. This is a document issued by the Food and Drug Administration to facility management at the conclusion of an inspection when an investigator has observed any conditions that, in their judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act.
In recent years, the PolyPeptide Group and other major manufacturers have been subject to such inspections. For instance, reports regarding FDA 483 for PolyPeptide Laboratories San Diego LLC on May 15, 2025, highlight the rigorous nature of FDA Inspection, Warning Letter, Form 483 Observation cycles. These inspections are a standard part of the industry, focusing on Good Manufacturing Practices (GMP). As a user of these products, I find it vital to understand that an FDA 483 is an observation rep by EJ AMBROSE · 1949 · Cited by 109 — A STUDY of polypeptides prepared by Leuchs's method1,2 is being carried out in this Laboratory. We have recently prepared the polypeptide I (below) by the ort, not a final agency determination, but it serves as a critical indicator of a company's commitment to quality systems. Tracking 483s helps stakeholders monitor the compliance trends of the organizations they rely on.
Scientific Significance: Polypeptides and Research
Beyond the regulatory scope, the number 483 frequently appears in academic literature concerning the structural analysis of proteins. A classic example is the foundational research titled "Evidence of chain folding in a synthetic polypeptide" and in keratin, which has been cited extensively since its publication.
In modern research, specific amino acid sequences are often identified by their position within a protein. For example, the Human PRAME 469-483 epitope peptide is a high-quality reagent used for the stimulation of antigen-specific T cells. Similarly, researchers working with Recombinant Orang-Utan DDX6 Protein often utilize fragments spanning residues 1-483. These tools are indispensable for those of us involved in protein assay testing and structural biology.
Distinguishing the Terms
To clarify the landscape for those exploring this topic:
Polypeptide Laboratories, Inc. [Torrance / United - FDA 483s* Polypeptides: These are chains of amino acids that form the building blocks of proteins. The study of vasoactive intestinal polypeptide (VIP) and its role in mediating circadian rh Carboxypeptidase Y pro-peptide (PF05388) - Pfam entry ythmicity remains a fascinating area of neurobiology.
* Peptide Chain Release Factor 1: This is a specialized protein that directs the termination of translation, a fundamental process in cellular bi Polypeptide Laboratories, Inc. [Torrance / United States of America]. Inspection End Date: September 26, 2001. FEI: 1000519239. ology.
* Analytical Context: Whether it is the isolation of the polypeptide chains of prekeratin or the design of anticandidal agents, the precision of the peptide synthesis The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. A global presence throughout the world assures process is paramount.
Personal Perspective on Quality
My interest in these materials stems from a commitment to high-quality standards. Whether I am reviewing data on the Polypeptide Laboratories, Inc. facility in Torrance or examining the technical specifications of a control fragment like the Human RPS6KC1 (aa 384-483), I prioritize transparency. Understanding the distinction between a regulatory 483 observation and the scientific identificatio Sep 22, 2022 — A US FDA Form 483 has revealed visible foreign particles in certain batches of drug product at Catalent's Bloomington, Indiana facility. n of a polypeptide sequence is key to navigating this complex field.
By maintaining awareness of both the regulatory environment and the underlying biochem Apr 21, 2021 — FDA inspectors identified nine conditions at Emergent BioSolutions' Maryland vaccine manufacturing facility that could lead to product quality issues. ical research, we can better appreciate the rigorous standards required to produce these complex molecules. The industry continues to evolve, and keeping informed about these specific identifiers—whether they refer to a regulatory filing or a specific amino acid sequence—is essential for any dedicated follower of peptide science.